Crystallise’s synthetic sample generation approach for the pharmaceutical industry is a cutting-edge solution that uses Spearman Rank Correlation and Cholesky decomposition techniques. With this method, Crystallise has created a sample of 1 million individuals that closely mirrors the characteristics of a real-world population to within 0.5% of the original population from the Health Survey for England.
By using Crystallise’s synthetic data, pharmaceutical companies can confidently model the potential impact of new interventions on clinical outcomes such as mortality or morbidity, where directly comparable clinical data is sparse or non-existent. This approach identifies indications where a new product is unlikely to be cost-effective, to help clients decide whether to proceed with expensive phase 3 clinical trials.
